Skip to main content
NewslettersWatchlist

Biontech Se ADR(BNTX-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low112.68
Day High115.93
Open:112.90
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
Motley Fool
BioNTech Se (BNTX) Q3 2024 Earnings Call Transcript
Motley Fool
Up Over 600% in 2024, Can Summit Therapeutics Stock Keep Rising?
MarketBeat
4 Reasons Pfizer Could Be a Value Play You Can't Miss
Newswire.ca
Pfizer Canada and BioNTech Receive Health Canada Approval of Omicron KP.2 Variant Adapted COVID-19 Vaccine
Motley Fool
Here's Why Everyone's Talking About Summit Therapeutics
Motley Fool
Should You Buy Novavax Stock After This Regulatory Win?
BayStreet.ca
Analysts Predict Strong Growth for Cancer Vaccine Market: Key Biotech Stocks to Consider
GlobeNewswire
New Research Reveals Emergence of New Variants of Coronavirus to Boost COVID-19 Therapeutics Market Growth
Motley Fool
Pfizer and BioNTech's Combo Shot Missed the Mark. Is It Time to Sell?
Motley Fool
Why Pfizer Stock Slumped on Friday
Motley Fool
BioNTech Se (BNTX) Q2 2024 Earnings Call Transcript
Stock Target Advisor
BioNTech’s Q2 Revenues Plummet Amid Declining COVID-19 Vaccine Demand
The Globe and Mail
The key to investing in an age of disasters
BayStreet.ca
Biotech Innovations Drive Pancreatic Cancer Treatment: Market Expected to Reach $7.4 Billion by 2032
Newswire.ca
Biotech Advances in 2024: Innovative Treatments Aim to Boost Pancreatic Cancer Survival Rates
BayStreet.ca
Advancements in Cancer Therapeutics: What to Expect from the Upcoming 2024 Oncology Conference
Motley Fool
Why Vaccine Stocks Rallied This Week
Reuters
Moderna wins COVID shot patent case against Pfizer-BioNTech in Europe
Motley Fool
BioNTech Se (BNTX) Q1 2024 Earnings Call Transcript
Motley Fool
BioNTech Se (BNTX) Q4 2023 Earnings Call Transcript
SYNDTGAM
BioNTech shifts focus toward cancer drug development after earnings, revenue plunge
TheNewswire.com
BNTX DEADLINE ALERT: ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages BioNTech SE Investors to Secure Counsel Before Important March 12 Deadline in Securities Class Action - BNTX

Profile

BioNTech SE is a biotechnology company. It develops and commercializes immunotherapies for cancer and other diseases. BioNTech SE is based in Mainz, Germany.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.